Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007007851) PERCUTANEOUSLY ABSORPTIVE OPHTHALMIC PREPARATION COMPRISING EPINASTINE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims
1 . A method for delivering epinast ±ne or a
pharmaceutically acceptable salt thereof to an anterior ocular segment of a mammalian subj ect, which comprises applying a percutaneously absorp tive preparation comprising epinastine or a pharmaceutically ac ceptable salt there of to the skin surface including the surface of an eyelid of tlxe subj ect, thereby causing transfer of a. therapeutically ef fective amount of epina stine or a pharmaceutically acceptable salt thereof fxom the preparation to trie anterior ocular s egment of the subj ect .

2 . The method o f claim 1, wherein the therapeutically/ effective amount of epinastine or a pharmaceutically
acceptable salt thereof is maintained in the anterior ocular segment of the subj ect for at least 8 hours .
3 . The method o f claim 1, wherein the therapeutically/ effective amount of epinastine or a pharmaceutically
acceptable salt thereof is maintained in the anterior ocul ar segment of the subj ect for at least 24 nours .
4 . The method o f claim 1, wherein the therapeuticall y/ effective amount of epinastine or a pharmaceutically
acceptable salt thereof is maintained in the anterior ocul ar segment of the subj ect for at least 16 hours after removal of the preparation from the skin .
5. A method for- preventing or treating an allergic e ye disease in a mammalian subj ect, which comprises applying a percutaneously absorptive preparation comprising epinastin e or a pharmaceutically acceptable salt thereof to the skin sur face inclu-ding the surface of an eyelid of trie subj ect, thereby causiLng transfer of a therapeutically effective amount of epinastine or a pharmaceutically acceptable salt thereof f rom the preparation to an anterior ocular segment of the subj e ct .

6. The method o f claim 5, wherein the therapeuticall y effective amount of epinastine or a pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of the subj ect for at least 8 hours .
7 . The method of claim 5, wherein the therapeutically effective amount of epinastine or a pharmaceut±cally
acceptable salt thereof is maintained in the anterior ocular segment of the subj ect for at least 24 hours .
8 . The method of claim 5, wherein the therapeutically effective amount of epinastine or a pharmaceutically
acceptable salt thereof is maintained in the anterior ocular segment of the subj ect for at least 16 hours a fter removal of the preparation from the skin - 9. Trie method of any of claims 1 to 8, wltierein the percutaneously absorptive preparation is an adϊiesive
preparation .
10. Txie method of claim 9, wherein the adhesive
preparation is applied to the skin surface for 0.5 to 24 hours .

11. A. percutaneously absorptive prepar-at ±on comprising epinastine or a pharmaceutica lly acceptable sa lt thereof for use in preventing or treating an allergic eye disease in a mammalian subject, which compxises applying it to the skin surface including the surface of an eyelid of the subj ect, thereby causing transfer of a therapeutically effective amount of epinastine or a pharmaceut ically acceptable salt thereof from the preparation to an anterior ocular seojment of the subj ect .
12. The preparation of claim 11, wherein the
therapeutically effective amount of epinastine or a
pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of th_e subject for at least 24 hours.
13. The preparation of claim 11, wherein, the
therapeutically effective amount of epinastine or a
pharmaceutically acceptable salt thereof is maintained in the anterior ocular segment of ttxe subject for at least 16 hours after removal o"f the preparation from the skin.

14 . The preparation of any of claims 11 to 13, wtierein the percutaneously aJbsorptive preparation is an adhesive
preparation .
15. The preparration of claim 3_ 4, which is applied to the skin surface for 0.5 to 24 hours .
16. A percutaneously absorptive adhesive preparation comprising epinastine or a pharmaceutically acceptable salt thereof for use in preventing or treating an allergic eye disease in a mammalian subj ect, which is applying to tlie skin suirface for 4 to 8 hours per day.
17 . A use of epinastine or a pharmaceutically acceptable salt thereof for the production of a percutaneously ab sorptive preparation for preventing or treating an allergic eye disease in a mammalian subj ect, which comprises applying it to the skin surface including the surface of an eyelid of th.e subj ect, thereby causing transfer of a therapeutically effective amount of epinastine or a pharmaceutically acceptable salt trxereof from the preparation to an anterior ocular segment of the subject .
18 . The use o f claim 17 , wherein the therapeutically ef fective amount of epinastine or a pharmaceutically
acceptable salt thereof is maintained in the anterior ocular segment of the subj ect for at least 24 hours .
19. The use o f claim 17 , wher ein the therapeut legally ef fective amount of epinastine or a. pharmaceutically
acceptable salt the reof is maintained in the anterior ocular segment of the subj ect for at least 16 hours after removal of th-e preparation from the skin .
20 . The use o f any of claims 17 to 19, wherein the percutaneously abso rptive preparation is an adhesive
preparation.
21 . The use o f claim 20, wherrein the adhesive preparation is applied to the s kin surface for 0 .5 to 24 hours .